Jonathan D. Cheng
Impact in
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Cells and Metastasis
Papers in
- Co-authors
- Tanguy Y. Seiwert (17 shared papers)Jared Lunceford (12 shared papers)Terrill K. McClanahan (6 shared papers)Laura Q.M. Chow (14 shared papers)Raanan Berger (11 shared papers)Erin Murphy (6 shared papers)Jennifer H. Yearley (5 shared papers)Sarina A. Piha‐Paul (8 shared papers)
- Journals
- Journal of Clinical Oncology (38 papers)Cancer Research (6 papers)Clinical Cancer Research (5 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)Journal of Medicinal Chemistry (3 papers)
- Partner nations
- United StatesSouth KoreaJapan
In The Last Decade
Jonathan D. Cheng
111 papers receiving 12.1k citations
Jonathan D. Cheng's Hit Papers
Peers
Comparison fields: 5 of 128
- Otorhinolaryngology 1.2k
- Oncology 7.4k
- Cancer Research 1.7k
- Immunology 2.4k
- Pulmonary and Respiratory Medicine 2.1k
Countries citing papers authored by Jonathan D. Cheng
This map shows the geographic impact of Jonathan D. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan D. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan D. Cheng more than expected).
Fields of papers citing papers by Jonathan D. Cheng
This network shows the impact of papers produced by Jonathan D. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan D. Cheng. The network helps show where Jonathan D. Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan D. Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 114 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Hit paper breakdown → | 2017 | 2429 |
| 2 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Hit paper breakdown → | 2016 | 1302 |
| 3 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Hit paper breakdown → | 2016 | 1135 |
| 4 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study Hit paper breakdown → | 2017 | 505 |
| 5 | PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer Hit paper breakdown → | 2017 | 464 |
| 6 | 2005 | 415 | |
| 7 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 334 |
| 8 | 2017 | 311 | |
| 9 | 2007 | 301 | |
| 10 | 2016 | 291 | |
| 11 | 2011 | 249 | |
| 12 | 2014 | 217 | |
| 13 | 2007 | 212 | |
| 14 | 2013 | 205 | |
| 15 | 2008 | 200 | |
| 16 | Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. | 2002 | 198 |
| 17 | 2006 | 159 | |
| 18 | 2019 | 157 | |
| 19 | 2018 | 148 | |
| 20 | 2005 | 138 |
About Jonathan D. Cheng
Jonathan D. Cheng is a scholar working on Oncology, Surgery, Otorhinolaryngology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 114 papers that have together received 12.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (36 papers), Peptidase Inhibition and Analysis (25 papers), Head and Neck Cancer Studies (20 papers), Esophageal Cancer Research and Treatment (11 papers), Lung Cancer Treatments and Mutations (10 papers), Neuropeptides and Animal Physiology (10 papers), Cancer Genomics and Diagnostics (9 papers) and Protease and Inhibitor Mechanisms (9 papers). The work is most often cited by research in Otorhinolaryngology (1.2k citations), Oncology (7.4k citations), Cancer Research (1.7k citations), Immunology (2.4k citations) and Pulmonary and Respiratory Medicine (2.1k citations). Jonathan D. Cheng has collaborated with scholars based in United States, South Korea and Japan. Frequent co-authors include Tanguy Y. Seiwert, Jared Lunceford, Terrill K. McClanahan, Laura Q.M. Chow, Raanan Berger, Erin Murphy, Jennifer H. Yearley, Sarina A. Piha‐Paul, Louis M. Weiner and Mark Ayers. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.